-
-
Call more information
660-596-2224 -
ASA Monitor August 2022, Vol. 86, 13. Trends FDA limits use of Johnson & Johnson COVID vaccine The U.S. Food and Drug Administration (FDA) has limited the authorized use of Johnson & Johnson’s Janssen COVID-19 vaccine to certain individuals due to risk of thrombotic events. The vaccine may still be used in people over the age […]
Read MoreAuthor: Patrick Giam, MD, FASA ASA Monitor August 2022, Vol. 86, 5. Author’s note: As the current Speaker of the House of Delegates, I probably should be writing an article about parliamentary process or governance issues in our society. I have done just that many times before, and I will probably do it next year. But […]
Read MoreAuthors: Dermot P. Maher, M.D., M.S., M.H.S. et al Anesthesiology August 2022, Vol. 137, 243–251. Background The authors estimate the probability of successful development and duration of clinical trials for medications to treat neuropathic and nociceptive pain. The authors also consider the effect of the perceived abuse potential of the medication on these variables. Methods This […]
Read MoreAuthors: Nil Ural, MD et al ASA Monitor August 2022, Vol. 86, 20–21. Surgical site infections (SSIs) occur in 2%-5% of patients and are a costly nosocomial occurrence. The rate varies and is dependent upon the type of wound. Risk factors for SSI include immunodeficiency, chronic steroid use, diabetes mellitus, extremes of age, and inpatient status […]
Read MoreAuthors: Dustin R. Long, MD et al ASA Monitor August 2022, Vol. 86, 19–20. Infection prevention and control (IPC) are critical elements of perioperative quality and safety. Healthcare-associated infection is the leading cause of postoperative complications and hospital readmissions (asamonitor.pub/3tk4yG9). Perioperative teams and pre-anesthesia clinics are uniquely positioned to implement interventions that reduce postoperative infection (Anesthesiology […]
Read More